

Area Prescribing Group report

APG meeting date: Friday 05 January 2024 **Quorate:** Yes

The items in this report are supported by the area prescribing group and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

Document links provided for any APG recommendations are temporarily hosted on the legacy Pan Mersey APC website as a pragmatic solution until such time as a Cheshire and Merseyside APG website is available. The [legacy Cheshire formulary](#) will also be updated to reflect these changes.

CMAPG governance documents are now hosted on the new [Prescribing](#) section of the NHS Cheshire and Merseyside website, which is currently being developed

Formulary and guidelines

Proposal	Notes	Approval
<p>Cheshire & Merseyside formulary chapter 3 – harmonisation of legacy formulary chapters and update.</p> <p>RAG designation: various</p> <p>APG subgroup: 12 Dec 2024</p> <p>APG: 05 Jan 2024</p>	<p>Full review and harmonisation of legacy Cheshire and Pan Mersey formulary chapter 3. This has been carried out separately to the currently ongoing Cheshire and Merseyside rapid formulary harmonisation process. It includes full updating and layout changes in addition to harmonisation, to inform processes for subsequent full update of the whole Cheshire and Merseyside formulary.</p>	<p>MOP: 18th January 2024, clinically supported and approved by ICB Medicines Optimisation and Pharmacy Group</p> <p>The new Cheshire and Merseyside formulary platform is in the final stages of development and a link to the new, harmonised chapter 3 will be circulated once this is fully functional.</p>

APG governance documents

Proposal	Notes	Approval
New Medicines Subgroup: Process for NICE TAs RAG designation: N/A APG subgroup: 08 Dec 2023 APG: 05 Jan 2024	For approval. Process for NICE TAs with Amber or Green RAG rating, to be incorporated into existing NMSG process for NICE TAs with Grey, Black or Red RAG rating.	MOP: 18th January 2024, clinically supported and approved by ICB Medicines Optimisation and Pharmacy Group

APG reports

Title	Notes	Approval
NICE TA adherence checklist November 2023	For noting.	MOP: 18th January 2024, noted by ICB Medicines Optimisation and Pharmacy Group

Carried forward

Proposal	Notes	Approval
<p>Daridorexant for treating long-term insomnia</p> <p>RAG designation: GREEN</p> <p>APG subgroup: 10 Nov 2023</p> <p>APG: 01 Dec 2023</p>	<p>Date of NICE TA publication: 18 Oct 2023</p> <p>Approval for implementation: 90 days</p> <p>Deadline for implementation: 16 Jan 2024</p> <p>Statement in line with TA922. It has been acknowledged that there is a lack of CBTi provision in Cheshire and Merseyside and therefore all eligible patients would progress to treatment with daridorexant.</p> <p>The APG expressed a concern that there is an alternative non-medical treatment that should be optimised, rather than progressing immediately to drug treatment.</p> <p>Based on the NICE Resource Impact Template, the cost of implementing TA922 for the Cheshire and Merseyside population is estimated to be £244,000 in 2023/24, £490,000 in 2024/25, £762,000 in 2025/26, £1,090,000 in 2026/27, and £1,421,000 in 2027/28 when it is assumed that steady state has been reached. This is based on drug costs alone and doesn't take into account any additional resource or training needed.</p>	<p>Clinically supported by ICB Medicines Optimisation and Pharmacy Group 14/12/2023.</p> <p>Escalated within ICB for approval decision in line with Standing Financial Instructions (SFI) and Scheme of Reservation and Delegation (SORD) for the ICB.</p> <p>90-day deadline not being met escalated within ICB.</p> <p>Approved by the ICB Director of Finance 23/01/2024.</p>

Proposal	Notes	Approval
<p>Tirzepatide for treating type 2 diabetes</p> <p>RAG designation: GREEN</p> <p>APG subgroup: 10 Nov 2023</p> <p>APG: 01 Dec 2023</p>	<p>Date of NICE TA publication: 25 Oct 2023</p> <p>Approval for implementation: 90 days</p> <p>Deadline for implementation: 23 Jan 2024</p> <p>Statement in line with TA924. Tirzepatide is a first in class dual GLP-1 and GIP receptor agonist. It is positioned an alternative to GLP-1 receptor agonists in the type 2 diabetes treatment pathway. There is currently work ongoing to harmonise the legacy RAG designations for GLP-1 agonists to green.</p> <p>Tirzepatide is not commercially available yet, but it is envisaged that uptake could be huge due to the supply issues with GLP-1 agonists and favourable glycaemic control and weight loss outcomes for tirzepatide.</p> <p>Based on the NICE Resource Impact Template, which estimates that that 50% of the current patient population receiving GLP-1 agonists will receive tirzepatide in place of their current GLP-1 treatment, the cost of implementing TA924 for the Cheshire and Merseyside population is estimated to be £325,000 in 2023/24, £979,000 in 2024/25, £1,550,000 in 2025/26, £1,566,000 in 2026/27, and £1,582,000 in 2027/28 when it is assumed that steady state has been reached.</p>	<p>Clinically supported by ICB Medicines Optimisation and Pharmacy Group 14/12/2023.</p> <p>Escalated within ICB for approval decision in line with Standing Financial Instructions (SFI) and Scheme of Reservation and Delegation (SORD) for the ICB.</p> <p>Approved by the ICB Director of Finance 23/01/2024.</p>